

Human BMP9/GDF-2 Protein

Cat. No. BMP-HM209

Description

Source	Recombinant Human BMP9/GDF-2 Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Ser320-Arg429.
Accession	Q9UK05
Molecular Weight	The protein has a predicted MW of 38.7 kDa. Due to glycosylation, the protein migrates to 45-48 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE

Formulation and Storage


Formulation	Lyophilized from 0.22 μm filtered solution in 4mM HCl. Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 $\mu\text{g}/\text{ml}$ is recommended. Dissolve the lyophilized protein in 4mM HCl.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Obesity drives the development of nonalcoholic fatty liver disease (NAFLD) characterized by hepatic steatosis. Several bone morphogenetic proteins (BMPs) except BMP9 were reported related to metabolic syndrome. BMP9 plays a critical role in regulating hepatic lipid metabolism in a PPAR α -dependent manner and may provide a previously unknown insight into NAFLD therapeutic approaches.

Assay Data


Bis-Tris PAGE



Human BMP9 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ELISA Data

Human BMP9, hFc Tag ELISA
0.2 μg Human BMP9, hFc Tag Per Well



Immobilized Human BMP9, hFc Tag at 2 $\mu\text{g}/\text{ml}$ (100 $\mu\text{l}/\text{Well}$) on the plate. Dose response curve for Biotinylated Anti-BMP9 Antibody, hFc Tag with the EC50 0.25 $\mu\text{g}/\text{ml}$ determined by ELISA.